Bristol-Myers kidney cancer drug fails late-stage trial
August 15, 2017 at 16:51 PM EDT
Aug 15 (Reuters) - Bristol-Myers Squibb Co said on Tuesday its combination drug to treat previously untreated patients with advanced or metastatic renal cell carcinoma, a type of kidney cancer, failed to meet one of the main goals of a late-stage trial.
